Kelly A. Romano's most recent trade in Dorman Products Inc was a trade of 1,070 Common Stock done . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dorman Products Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 1,070 | 10,861 (0%) | 0% | 0 | Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Dorman Products Inc | Kelly A. Romano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.02 per share. | 16 May 2025 | 46 | 9,791 (0%) | 0% | 132.0 | 6,073 | Common Stock |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 5,695 | 24,652 (0%) | 0% | 0 | UGI Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 2.42 per share. | 21 Jun 2024 | 27,400 | 80,715 | - | 2.4 | 66,179 | Common Stock |
| Athira Pharma Inc | Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 2.26 per share. | 21 Jun 2024 | 15,000 | 53,315 | - | 2.3 | 33,872 | Common Stock |
| Dorman Products Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 1,471 | 9,837 (0%) | 0% | 0 | Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Dorman Products Inc | Kelly A. Romano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.34 per share. | 17 May 2024 | 47 | 8,366 (0%) | 0% | 91.3 | 4,293 | Common Stock |
| UGI Corp. | Romano A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 12,890 | 12,890 | - | - | Options (Right to Buy) | |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 4,470 | 18,001 (0%) | 0% | 0 | UGI Common Stock | |
| Dorman Products Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 1,510 | 8,413 (0%) | 0% | 0 | Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Dorman Products Inc | Kelly A. Romano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.55 per share. | 18 May 2023 | 38 | 6,903 (0%) | 0% | 86.6 | 3,289 | Common Stock |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 5,670 | 5,670 | - | - | Options (Right to Buy) | |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 2,600 | 12,761 (0%) | 0% | 0 | UGI Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 3.29 per share. | 02 Dec 2022 | 30,000 | 38,315 | - | 3.3 | 98,700 | Common Stock |
| Dorman Products Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 1,223 | 6,941 (0%) | 0% | 0 | Common Stock | |
| Dorman Products Inc | Kelly A. Romano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.06 per share. | 25 May 2022 | 33 | 5,718 (0%) | 0% | 98.1 | 3,236 | Common Stock |
| Athira Pharma Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 13.11 per share. | 31 Mar 2022 | 8,000 | 8,315 | - | 13.1 | 104,880 | Common Stock |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 6,050 | 6,050 | - | - | Options (Right to Buy) | |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 2,300 | 9,784 (0%) | 0% | 0 | UGI Common Stock | |
| Dorman Products Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 1,064 | 5,751 (0%) | 0% | 0 | Common Stock | |
| Dorman Products Inc | Kelly A. Romano | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.02 per share. | 13 May 2021 | 44 | 4,687 (0%) | 0% | 103.0 | 4,533 | Common Stock |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 8,860 | 8,860 | - | - | Option (Right to Buy) | |
| UGI Corp. | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 2,870 | 7,268 (0%) | 0% | 0 | UGI Common Stock | |
| Athira Pharma Inc | Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 27,742 | 27,742 | - | - | Stock Option (Right to Buy) |